ResultsIQ

ResultsIQ › Latest results › Vijaya Diagnostic Centre Limited

Vijaya Diagnostic Centre Limited Q4 FY25 results deck summary

NSE: VIJAYA · BSE: 543350

Results deck of 12 May 2025, summarised by AI from the filing.

Vijaya Diagnostic FY25 revenue ₹6,813.9 cr (+24.4%), PAT ₹1,430.8 cr (+20.4%); 6 new hubs launched, 3 more expected in 3-4 months.

Key takeaways

  1. FY25 revenue ₹6,813.9 cr (FY24: ₹5,478.1 cr, +24.4%)
  2. Expansion 6 hubs launched in last 2 months; 3 more in West Bengal expected within 3-4 months
  3. Q4 margin EBITDA margin 39.8% (Q4 FY24: 40.7%)
  4. Growth driver Organic growth 18.9% excluding PH

Original filing on BSE

Vijaya Diagnostic Centre Limited Q1 FY27 results

As filed: Revenue ₹231 cr (+23% year on year), EBITDA ₹98.5 cr (+35% year on year), PAT ₹53.1 cr (+36% year on year), EBITDA margin 42.7% (+383 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹219 cr (+27% year on year), EBITDA ₹95.5 cr (+40% year on year), PAT ₹47.9 cr (+37% year on year), EBITDA margin 43.5% (+423 bps). Score 88 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 423 bps year on year. Revenue rose ₹46.4 cr on a year ago, more than the ₹18.0 cr it added the year before. Share price after the results: +17.5% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹205 cr (+21% year on year), EBITDA ₹86.1 cr (+28% year on year), PAT ₹43.2 cr (+23% year on year), EBITDA margin 41.9% (+229 bps). Score 64 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 229 bps year on year. Revenue rose ₹36.2 cr on a year ago, more than the ₹36.0 cr it added the year before. Share price after the results: −0.3% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹202 cr (+10% year on year), EBITDA ₹82.0 cr (+9% year on year), PAT ₹43.0 cr (+2% year on year), EBITDA margin 40.6% (−39 bps). Score 26 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 39 bps year on year. Revenue rose ₹19.0 cr on a year ago, against ₹44.0 cr the year before. Share price after the results: −0.2% in 30 days (Nifty 500: +0.5%).
  • Q1 FY26: Revenue ₹188 cr (+21% year on year), EBITDA ₹73.0 cr (+20% year on year), PAT ₹39.0 cr (+22% year on year), EBITDA margin 38.8% (−27 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin fell 27 bps year on year. Revenue rose ₹32.0 cr on a year ago, against ₹35.0 cr the year before. Share price after the results: +0.7% in 27 days (Nifty 500: −3.2%).
  • Q4 FY25: Revenue ₹173 cr (+12% year on year), EBITDA ₹68.0 cr (+8% year on year), PAT ₹35.0 cr (+3% year on year), EBITDA margin 39.3% (−134 bps). Score 23 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 134 bps year on year. Revenue rose ₹18.0 cr on a year ago, against ₹34.0 cr the year before. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹169 cr (+27% year on year), EBITDA ₹67.0 cr (+26% year on year), PAT ₹35.0 cr (+35% year on year), EBITDA margin 39.6% (−20 bps). Score 72 of 100, Above trend. EBITDA margin fell 20 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter.
  • Q2 FY25: Revenue ₹183 cr (+32% year on year), EBITDA ₹75.0 cr (+29% year on year), PAT ₹42.0 cr (+24% year on year), EBITDA margin 41.0% (−74 bps). Score 71 of 100, Above trend. EBITDA margin fell 74 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Vijaya Diagnostic Centre Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.